Affinia Therapeutics offers a capsid engineering platform that designs adeno‑associated virus (AAV) vectors with improved tissue tropism, reduced immunogenicity, and GMP‑compatible manufacturability. The platform combines directed evolution, computational modeling, and high‑throughput screening to generate high‑titer, high‑purity vectors that can be integrated into existing gene‑therapy programs for preclinical and clinical development.
Funding
$40M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Gene therapy programs often struggle with adeno-associated virus (AAV) vectors that exhibit limited tissue tropism, provoke immune responses, or are difficult to produce at scale, leading to suboptimal safety and efficacy profiles for patients.
Solution
Affinia Therapeutics provides a capsid engineering platform that creates novel AAV vectors with enhanced tropism for target tissues and improved manufacturability. By applying high‑throughput screening, structure‑guided design, and proprietary bioinformatics, the company identifies capsid variants that achieve higher transduction efficiency while reducing immunogenicity. The engineered vectors are compatible with standard GMP production workflows, enabling scalable manufacturing for clinical programs. Affinia’s platform can be integrated into existing gene‑therapy pipelines, allowing partners to accelerate preclinical development and advance more effective genetic medicines across multiple disease indications.
Target Audience
Primary customers are biotech and pharmaceutical companies developing AAV‑based gene therapies, as well as academic research groups and contract manufacturing organizations seeking vectors with superior tissue targeting and production scalability.
Features
- Rational capsid design pipeline combining directed evolution and computational modeling to optimize tissue specificity
- High‑throughput in vitro and in vivo screening assays that quantify transduction efficiency and immune profile
- Scalable GMP‑compatible production process delivering high‑titer, high‑purity AAV vectors
- Modular vector backbone compatible with a wide range of therapeutic payloads (single‑strand, self‑complementary, and dual‑vector formats)
- Integrated bioinformatics suite for predictive capsid‑host interactions and manufacturability assessment
- Preclinical validation package including biodistribution, efficacy, and safety studies in relevant animal models
- IP‑free licensing options and custom development services tailored to partner therapeutic programs